Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with <i>EGFR</i> Exon 20 Insertion Mutations.

Patients treated in the first line setting experienced a worse outcome in terms of both PFS and OS; however, they did not reach statistical significance likely because of the low number of patients being compared (PFS: 1.6 months for first line versus 2.7 months for second line, p = 0.16—OS: 2.0 months for first line versus 8.1 months for second line, p = 0.09) ( Figure 2 B,E).

also in 111,027 other papers

When patients were classified by whether they had received treatment with ICB, median OS was shorter, at the limit of significance, for patients treated with immunotherapy versus those who did not receive ICB treatment, being 12.9 months (95% CI 13.3–35.0) versus 25.2 months (95% CI 3.2–28.2) ( p = 0.08), respectively ( Figure 3 B).

also in 326 other papers